Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.85), $0.05 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $20 million versus the consensus estimate of $19.44 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.